Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 5,722

Document Document Title
WO/2019/161010A1
The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions com...  
WO/2019/160315A1
The present invention relates to a heterocyclic compound of formula 1 and an organic light emitting device comprising the same.  
WO/2019/161157A1
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).  
WO/2019/156903A1
Disclosed are compounds of Formula 1, wherein J is and R1a, R1b, R2, R3, R4, R5, R6, R7, R8, R14, R15, R16, Q and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for c...  
WO/2019/154663A1
The present invention relates to the use of compounds of formula I, wherein the variables are defined as given in the description and claims. The invention further relates to the compounds I and composition for compounds of formula I.  
WO/2019/150305A1
Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and compounds (I) for use as inhibitors of the KRAS protein for the tretament of cancer.  
WO/2019/145719A1
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of For...  
WO/2019/138332A1
Process for the preparation of a disubstituted diaryloxybenzoheterodiazole compound having general formula (I).  
WO/2019/134667A1
A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically accep...  
WO/2019/121691A1
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...  
WO/2019/126505A1
This application relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, which are inhibitors of ΡΙ3Κ-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular dis...  
WO/2019/121159A1
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, formula...  
WO/2019/121373A1
The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of pyrimidine compounds ...  
WO/2019/124903A1
An organic light emitting device comprising a compound represented by formula 1 as a light emitting auxiliary layer material and an electronic device comprising the same are disclosed. As the compound represented by formula 1 is comprise...  
WO/2019/122345A1
The present invention relates to benzamide compounds of formula I wherein the variables are defined as in the claims and the description, the N-oxides and salts thereof,and to compositions comprising the same. The invention also relates ...  
WO/2019/113693A1
Compounds that are inhibitors of retinoic acid inducible P450 (CYP26) enzymes. The compounds have retinoid activity, are resistant to CYP26-mediated catabolism, act as inhibitors of CYP26B1, and are used for treating diseases that are re...  
WO/2019/101719A1
The present invention relates to triarylamine compounds according to a defined formula. The present invention further relates to methods for producing said compounds, to the use of the compounds in electronic devices, and to electronic d...  
WO/2019/101039A1
Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tau...  
WO/2019/099307A1
The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-me...  
WO/2019/099777A2
Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to...  
WO/2019/097487A1
The present disclosure relates to derivatives of strigolactone and formulations thereof. The present disclosure also relates to methods of treating a plant to improve, for example, the yield, growth, or vigor of a plant. The disclosed st...  
WO/2019/093623A1
The present invention provides a novel heterocyclic compound and an organic light-emitting diode using the same.  
WO/2019/085758A1
Disclosed in the present invention are a ketone-containing compound and applications thereof in organic electroluminescent devices. The compound consists of ketone and spiroanthracenefluorene groups, has a very deep HOMO energy level and...  
WO/2019/090088A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/081299A1
The present invention relates to novel amine substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compos...  
WO/2019/082717A1
The purpose of the present invention is to provide: a novel curable compound which can be expected to be used as a raw material for photocurable resins and thermosetting resins; a method for synthesizing said compound; a resin compositio...  
WO/2019/081477A1
The invention relates to substituted pyrazoles of general formula (I) or salts thereof, wherein the groups of general formula (I) are defined as cited in the description, and to the use thereof as herbicides, in particular for controllin...  
WO/2019/076316A1
Provided is a preparation method for a tyrosine kinase inhibitor and an intermediate thereof. Specifically, a preparation method for a cyanoquinoline compound is provided. The method has a high yield, good product purity, and mild reacti...  
WO/2019/073325A1
The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).  
WO/2019/074870A1
The present disclosure relates compositions and methods for combinatorial drug discovery in nanoliter droplets. More particularly, the disclosure relates to novel synergistic agents that increase efficacy of antibiotic agents to treat ba...  
WO/2019/068783A1
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.  
WO/2019/068782A1
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.  
WO/2019/070044A1
A purpose of the present invention is to provide a heterocyclic compound that has an AMPA receptor function enhancing action, and can be expected to be useful as a prevention or treatment for depression, Alzheimer's disease, schizophreni...  
WO/2019/065928A1
The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of inflammatory diseases of the central nervous system, or a pharmacologically acceptable salt thereof. Provided is a compound represent...  
WO/2019/054386A1
Provided is a heterocyclic compound represented by general formula (I), or a pharmacologically acceptable salt of the heterocyclic compound. In general formula (I): X represents O or NH; R1 represents a substituted or unsubstituted aryl ...  
WO/2018/139767A9
The present invention provides a novel amine-based compound and an organic light emitting device using the same.  
WO/2019/046316A1
The present invention relates to compounds of formula (I) (shown below) useful as inhibitors of phosphatidylinositol- 3 -phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.  
WO/2019/045581A1
New 5-aminotetrazole derivatives with antimicrobial and antifungal activity are disclosed.  
WO/2019/037860A1
Compounds of formula (I) wherein A, R, W, Q, L, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2019/038717A1
The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1,R2, Rx, XI, n, nl, and q are as defined herein, methods of making ...  
WO/2019/040389A1
The present invention relates novel furan based amine cross-linkers with improved thermomechanical and water barrier properties. The novelty of this invention is the use of aromatic, and hydrophobic aliphatic aldehydes to bridge two furf...  
WO/2019/040104A2
The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.  
WO/2019/035408A1
The present invention provides a method for producing a compound (i) having a group represented by a partial structure (A), a partial structure (AI), a partial structure (D), or a partial structure (DI), and a group represented by a part...  
WO/2019/034686A1
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; ...  
WO/2019/036534A1
Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising t...  
WO/2019/031880A1
The present invention relates to kidamycin derivative L1-95-1, and a composition for preventing or treating cancer, containing the same as an active ingredient. L1-95-1 has inhibited cell proliferation and EGF-induced malignization of JB...  
WO/2019/030604A1
Provided is a novel compound. Also provided is a light-emitting element having excellent light-emitting efficiency and element service life. The compound is an organic compound represented by the general formula (G0) and having a dibenzo...  
WO/2019/027040A1
A compound represented by formula (1) (in the formula, R1-R8, R11-R18, R21-R28, R31-R38, X, Y, L1, L2, L3, and Ar are as defined in the specification) provides an organic electroluminescent element having a low drive voltage and exceptio...  
WO/2019/023450A1
Described herein are compounds of the formulae (l)-(lII) and (la)-(llla) and pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods usin...  
WO/2019/016269A1
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.  

Matches 451 - 500 out of 5,722